ABOUT THIS EPISODE
Dr. Remo Panaccione, an internationally recognized expert in clinical trials discusses the recent data on vedolizumab and anti-IL23 therapies and how those changes impact clinical decision making in IBD
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OTHER EPISODES IN THIS PODCAST
Pradeep Bhandari from Portsmouth (UK) on recent BSGE guidelines of chromoendoscopy, co-hosted by Raf Bisschops.
Jean-Fred Colombel, Mount Sinai Hospital New York City, USA, talks about his biography and personal pathway in IBD and options of very early diagnosis of IBD and strategies to prevent the onset of IBD (interception) and early management of IBD
Bruce Sands, Mount Sinai Hospital New York City, USA, talks about his biography and personal pathway in IBD and options of breaking the therapeutic ceiling in IBD including combination therapy, treat to target and early treatment
Matthieu Allez, Montreal, talks about the management of postoperative Crohn's disease, prediction of relapse rates, monitoring strategies in the postoperative setting, risk factors for postoperative recurrence and potential strategies to prevent recurrence
Disclaimer: The podcast and artwork embedded on this page are from Axel Dignaß, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
